Intelligent Bio Solutions Inc. (INBS) Key Metrics
INBS valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $5.0M
- Enterprise value
- $3.7M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 1.2
- Price / book
- 1.1
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 4.30
INBS key metrics, FY2017–FY2026
Fiscal year ended June 30, 2026 · U.S. dollarsINBS valuation Price multiples at each fiscal year-end price.
INBS returns How much profit the business earns on the capital it uses.
INBS per-share figures Results divided by the shares outstanding at year-end.
INBS financial health Debt, liquidity and how easily interest is covered.
INBS efficiency & capital use Working capital cycle and where the cash goes.
INBS valuation history
INBS returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
INBS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
INBS cash returned to shareholders
INBS price vs earnings per share
INBS key metrics
FY2017–FY2026| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $3.4M | — | — | — | $23.30B | — | — | — | — | — |
| Enterprise value | $1.2M | — | — | — | $23.29B | — | — | — | — | — |
| Price / sales | 0.8 | — | — | — | — | — | — | — | — | — |
| Price / book | 0.6 | — | — | — | — | — | — | — | — | — |
| EV / sales | 0.3 | — | — | — | — | — | — | — | — | — |
| Earnings yield | −367.8% | — | — | — | −0.0% | — | — | — | — | — |
| Free cash flow yield | −356.6% | — | — | — | −0.0% | — | — | — | — | — |
| Share price at fiscal year-end | $2.29 | $17.20 | $19.20 | $333.60 | $1,588.80 | $9,456.00 | — | — | — | — |
| Per share | ||||||||||
| Revenue per share | $2.86 | — | — | — | $0.00 | — | — | — | — | — |
| Earnings per share | −$8.44 | — | — | — | −$0.57 | — | — | — | — | — |
| Operating cash flow per share | −$8.10 | — | — | — | −$0.23 | — | — | — | — | — |
| Free cash flow per share | −$8.18 | — | — | — | −$0.25 | — | — | — | — | — |
| Cash per share | $2.71 | — | — | — | $0.56 | — | — | — | — | — |
| Book value per share | $3.74 | — | — | — | $0.45 | — | — | — | — | — |
| Tangible book value per share | $1.84 | — | — | — | $0.45 | — | — | — | — | — |
| Capex per share | $0.09 | — | — | — | $0.03 | — | — | — | — | — |
| Debt per share | $1.24 | — | — | — | — | — | — | — | — | — |
| Shares outstanding | 1.5M | — | — | — | 14.7M | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −292.3% | −186.6% | −167.5% | −205.5% | −76.9% | −142.6% | — | — | — | — |
| Return on invested capital (ROIC) | −356.0% | −309.8% | −221.1% | −801.0% | — | −411.1% | — | — | — | — |
| Return on assets (ROA) | −123.1% | −96.0% | −84.2% | −93.6% | −48.6% | −57.8% | −154.6% | −304.2% | −317.4% | −51.0% |
| Return on tangible assets | −136.0% | −237.0% | −108.0% | −208.5% | −67.2% | −32.2% | −150.0% | −315.2% | −201.1% | −51.0% |
| Free cash flow margin | −285.9% | −324.6% | −314.7% | −627.2% | — | −570.4% | −264.2% | — | — | — |
| Financial health | ||||||||||
| Total debt | $1.8M | $281,805 | $1.1M | $1.9M | — | $137,812 | $5.1M | $5.1M | $4.8M | $3.5M |
| Cash & short-term investments | $4.0M | $1.0M | $6.3M | $1.5M | $8.2M | $12.6M | $427,273 | $197,940 | $418,420 | $56,033 |
| Net debt | −$2.2M | −$738,104 | −$5.2M | $378,053 | −$8.2M | −$12.4M | $4.7M | $4.9M | $4.4M | $3.5M |
| Debt / equity | 0.33 | 0.09 | 0.14 | 0.50 | — | 0.01 | — | — | — | — |
| Debt / assets | 0.15 | 0.03 | 0.08 | 0.18 | — | 0.01 | 2.07 | 2.20 | 1.94 | 5.30 |
| Current ratio | 1.44 | 0.77 | 1.57 | 0.66 | 2.33 | 4.94 | 0.06 | 0.37 | 0.45 | 0.10 |
| Quick ratio | 1.35 | 0.65 | 1.42 | 0.49 | 2.33 | 5.82 | −0.18 | 0.05 | 0.08 | 0.10 |
| Interest coverage | — | -174.8 | -61.5 | -56.3 | — | -5.1 | -5.9 | -10.1 | -10.1 | — |
| Working capital | $2.2M | −$1.2M | $3.1M | −$2.0M | $6.2M | $14.5M | −$7.2M | −$4.0M | −$3.1M | −$5.9M |
| Invested capital | $3.3M | $2.3M | $3.2M | $4.2M | −$1.7M | $2.6M | −$480,084 | $318,350 | $46,038 | −$2.4M |
| Tangible asset value | $2.5M | −$976,495 | $3.8M | −$1.6M | $6.5M | $15.0M | −$5.2M | −$4.0M | −$3.1M | −$5.9M |
| Net current asset value | $446,226 | −$1.3M | $2.9M | −$2.8M | $5.1M | $11.4M | −$7.2M | −$4.0M | −$3.1M | −$5.9M |
| Graham net-net per share | −$1.23 | — | — | — | $0.29 | — | — | — | — | — |
| Capital allocation | ||||||||||
| Share buybacks (net) | — | — | — | $14,407 | — | — | — | — | — | — |
| Capex / revenue | 3.0% | 7.6% | 7.1% | 40.2% | — | 0.0% | 201.4% | — | — | — |
| Capex / depreciation | 0.11 | 0.19 | 0.18 | 0.52 | 0.39 | 0.00 | 0.39 | 6.57 | 0.00 | 0.00 |
| Stock-based compensation / revenue | 4.6% | 7.8% | 7.4% | 20.7% | — | — | 476.8% | — | — | — |
| R&D / revenue | 80.0% | 78.5% | 53.8% | 40.4% | — | 193.7% | 311.6% | — | — | — |
| SG&A / revenue | 249.2% | 291.0% | 297.5% | 391.5% | — | 169.6% | 1,286.6% | — | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | 106.0 | 154.1 | 106.2 | 479.1 | — | 195.2 | 110.3 | — | — | — |
| Days of inventory on hand | 88.8 | 142.8 | 190.2 | 192.3 | — | — | — | — | — | — |
| Days payables outstanding | 135.7 | 151.6 | 194.7 | 375.1 | — | — | — | — | — | — |
| Cash conversion cycle (days) | 59.1 | 145.3 | 101.8 | 296.2 | — | — | — | — | — | — |
| Receivables turnover | 3.44 | 2.37 | 3.44 | 0.76 | 0.00 | 1.87 | 3.31 | 0.00 | 0.00 | — |
| Payables turnover | 2.69 | 2.41 | 1.88 | 0.97 | 0.00 | 0.00 | 0.00 | — | — | — |
| Inventory turnover | 4.11 | 2.56 | 1.92 | 1.90 | — | — | 0.00 | — | — | — |
| Asset turnover | 0.42 | 0.28 | 0.26 | 0.11 | 0.00 | 0.16 | 0.08 | 0.00 | 0.00 | 0.00 |
| Average receivables | $1.2M | $1.3M | $905,756 | $1.6M | $2.3M | $1.1M | $57,048 | $65,492 | $36,481 | — |
| Average payables | $804,854 | $749,798 | $899,280 | $956,062 | $1.0M | $919,735 | $666,648 | $508,593 | $253,320 | $339,174 |
| Average inventory | $526,896 | $706,376 | $878,722 | $489,954 | −$1.6M | −$664,108 | $1.9M | $2.0M | $2.0M | — |
| Intangibles / total assets | 23.4% | 45.9% | 31.7% | 50.8% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from INBS's annual financial statements (latest annual report filed August 19, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
INBS valuation and financial ratios
Intelligent Bio Solutions earned a return on equity of −292.3% and a return on invested capital of −356.0% in fiscal 2026. It ended the year with $1.8 million of debt and $4.0 million in cash and short-term investments, a net cash position of $2.2 million.
See the INBS income statement, the INBS chart for price history, or the INBS stock overview for the latest quote and news.
INBS key metrics FAQ
What is Intelligent Bio Solutions's return on equity?
Intelligent Bio Solutions's return on equity (ROE) was −292.3% in fiscal 2026: net income of -$12.4 million on average shareholders' equity of $4.3 million.
What is Intelligent Bio Solutions's ROIC?
Intelligent Bio Solutions's return on invested capital was −356.0% in fiscal 2026, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Intelligent Bio Solutions have?
Intelligent Bio Solutions had total debt of $1.8 million at the end of fiscal 2026, a debt-to-equity ratio of 0.33 and more cash than debt.
What is Intelligent Bio Solutions's free cash flow yield?
Intelligent Bio Solutions generated -$12.1 million of free cash flow in fiscal 2026, a free cash flow yield of −356.6% on its market value at year-end ($3.4 million).
What is Intelligent Bio Solutions's current ratio?
Intelligent Bio Solutions's current ratio was 1.44 at the end of fiscal 2026: current assets were 1.44 times current liabilities.